TEVA PHARMACEUTICAL INDUSTRIES news, videos and press releases
For more news please use our advanced search feature.
TEVA PHARMACEUTICAL INDUSTRIES - More news...
TEVA PHARMACEUTICAL INDUSTRIES - More news...
- Teva Settles Price Fixing Charges With U.S. DOJ
- Teva Reports Second Quarter 2023 Financial Results
- Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
- Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
- Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
- Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
- Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
- Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
- Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
- Teva Concludes Nationwide Opioids Settlement Agreement
- Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
- Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
- Teva Launches New “Pivot to Growth” Strategy
- AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
- Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
- Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
- U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
- Teva to Launch New Growth Strategy at Investor Day
- Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
- Complete Response Letter Received for AVT02 Biologics License Application
- Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
- Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
- Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
- Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
- Teva to Present at the Barclays Global Healthcare Conference
- Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
- Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
- Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
- Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
- Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
